Contract facts
FederalEO 14398 - (PACS) IDIQ - REGULATORY REVIEW SUPPORT is a federal award for Fda Office Of Acq Grant Svcs held by Kaiva Strategies, LLC. Estimated value $713K ($713K obligated). Current period of performance ends Sep 29, 2027. Place of performance: COLLEGE PARK MD.
EO 14398 - (PACS) IDIQ - REGULATORY REVIEW SUPPORT
Recompete timing
PublicCurrent PoP ends Sep 29, 2027 (404 days remaining). Agencies typically plan 12–18 months ahead — position before the PoP clock runs out.
Incumbent footprint
Public recordKaiva Strategies, LLC — $90.5M obligated across 68 awards (firm-wide, all agencies).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75F40126F19024?
75F40126F19024 (PACS support) is a Fda Office Of Acq Grant Svcs award with a potential value of $713K, currently held by Kaiva Strategies, LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75F40126F19024?
Fda Office Of Acq Grant Svcs awarded 75F40126F19024 to Kaiva Strategies, LLC (potential $713K).
Who is the incumbent on 75F40126F19024?
Kaiva Strategies, LLC is the incumbent with $90.5M across 68 related awards in SCOUT’s public footprint. The current period of performance ends Sep 29, 2027.
When does Kaiva Strategies, LLC’s 75F40126F19024 come up for recompete?
SCOUT tracks a period-of-performance end of Sep 29, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.
